Date: Thursday 31th August
Time: 7.00am to 8.00am
Title: The role of modern insulins and technology in the management of Type 1 and Type 2 diabetes: An ever evolving landscape
Content: The type 2 diabetes treatment landscape is constantly changing in terms of the availability of new clinical data and new classes of glucose lowering therapies. As a result, treatment guidelines, TGA indications and PBS restrictions are also in a state of constant evolution. Given this changing landscape and availability of modern insulins, where insulin fits into the current management of T2D and how can it be used in conjunction with other glucose lowering therapies, is challenging to elucidate. There have also been significant advances in the type 1 diabetes space with new insulins and devices evolving and better able to more closely mimic the physiological response of a person without diabetes, after a meal.
This symposium will focus on balancing efficacy and safety when using modern insulins alone or in combination with other glucose lowering agents to manage type 2 diabetes and advances in treatments for type 1 diabetes including pumps, closed loop systems, artificial pancreas and new insulins
Topic 1: Use of modern insulin in combination with other glucose lowering agents to manage type 2 diabetes
Topic 2: When is insulin therapy most appropriate for managing type 2 diabetes?
Topic 3: Advancements in treatments for type 1 diabetes including pumps, closed loop systems, artificial pancreas, new insulins
Speakers: Dr Ted Wu and Professor Tim Jones
Chair: Professor Timothy Davis (Consultant Physician and Endocrinologist, Fremantle Hospital)
This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.
This session is supported and organised by